This study allows for an understanding of differences in response rates and adverse events (AEs) of methylphenidate (MPH) and atomoxetine (ATX) in a real-world clinical context.

Overall, MPH was found to be more effective and better tolerated than ATX.

The rate of AEs during MPH treatment was higher in young children and lower in those over 10 years of age.